Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial Phase Eligible Participant Official Title Drugs in Trial Location
NCT03180307IIINewly diagnosed stage III ovarian cancerA Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian CancerView DrugsArizona, California, Florida, Maryland, Michigan, Minnesota, Missouri, Ohio, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action
OTL38fluorescent imaging ligand OTL38Folate receptor imaging agent
NCT03602859IIINewly diagnosed stage III/IV non-mucinous ovarian cancer (neo-adjuvant or adjuvant and maintenance)ENGOT-0V44 The FIRST (First-line Ovarian Cancer Treatment With Niraparib Plus TSR-042) Study: A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerView DrugsAlaska, California, Connecticut, Florida, Illinois, Louisiana, Maryland, Massachusetts, Minnesota, Montana, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
NiraparibMK4827, ZejulaPARP inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
TSR-042anti-PD-1 monoclonal antibody TSR-042, ANB011, DostarlimabBlocks PD-L1/2 inhibition of T cells
NCT03737643IIINewly diagnosed stage III/IV high grade non-mucinous ovarian cancer (neo-adjuvant or adjuvant and maintenance)A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).View DrugsCalifornia, Colorado, Florida, Georgia, Illinois, Indiana, Maryland, Michigan, Missouri, Nevada, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Utah
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
OlaparibAZD2281, LynparzaPARP inhibitor
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT02122185IINewly diagnosed stage III/IV ovarian cancer (neo-adjuvant or adjuvant and maintenance)A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal CancerView DrugsAlabama, California, Illinois, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitor
MetforminFortamet, Glucophage, Glumetza, RiometAMP-activated protein kinase (AMPK) activator
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT02437812IINewly diagnosed stage II-IV ovarian cancerA Phase II, Open-Label, Non-Randomized, Pilot Study of Paclitaxel, Carboplatin and Oral Metformin for Patients Newly Diagnosed With Stage II-IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CarcinomaView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
MetforminFortamet, Glucophage, Glumetza, RiometAMP-activated protein kinase (AMPK) activator
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT02520154IINewly diagnosed stage III/IV high grade non-mucinous ovarian cancer (neo-adjuvant)Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian CancerView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02834975IINewly diagnosed stage III/IV high grade ovarian cancer (neo-adjuvant)Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant ChemotherapyView DrugsFlorida
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02766582IINewly diagnosed stage III/IV ovarian cancer after suboptimal debulking surgeryPhase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian CancerView DrugsWisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
PembrolizumabMK3475, SCH 900475, Lambrolizumab, KeytrudaBlocks PD-L1/2 inhibition of T cells
NCT02033616IINewly diagnosed stage III/IV ovarian cancerPhase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary TherapyView DrugsCalifornia, Colorado
Drug(s) in Trial Other Drug Names Main Known Action
AVOVA-1TAA-loaded autologous dendritic cell vaccine, Autologous Dendritic Cells Loaded With Autologous Tumor Associated AntigensAnti-tumor immune response
NCT03531645IINewly diagnosed stage III/IV low grade serous ovarian cancer (neo-adjuvant)A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous CarcinomaView DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitor
FulvestrantFaslodex, ICI 182,780, ZD9238ER antagonist (SERD)
NCT03206645IbNewly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant)Phase 1B Trial With PTC-596 in High-Grade Serous Ovarian Cancer: a Targeted Approach Toward Chemoresistant Stem-Like Cancer CellsView DrugsOklahoma
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
PTC596polycomb ring finger oncogene inhibitor PTC596, BMI1 inhibitor PTC596BMI1 inhibitor
NCT03206177IbNewly diagnosed, persistent, or recurrent ovarian carcinosarcomaFeasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or OvaryView DrugsOklahoma
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
GalunisertibLY2157299TGFBR1 antagonist
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT02713386I/IINewly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant)A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerView DrugsFlorida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Nebraska, New Jersey, New Mexico, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Virginia, Washington, West Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
RuxolitinibINCB18424, Jakafi, oral Janus-associated kinase inhibitor INCB18424, oral JAK inhibitor INCB18424JAK1/2 kinase inhibitor
NCT02726997I/IINewly diagnosed stage III/IV high grade non-mucinous ovarian cancer (neo-adjuvant)Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)View DrugsTexas
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cells
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03394885I/IINewly diagnosed stage III-IV ovarian cancer (neo-adjuvant; inc expansion)Atezolizumab in Combination With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients With Newly-Diagnosed Advanced-Stage Epithelial Ovarian CancerView DrugsNorth Carolina
Drug(s) in Trial Other Drug Names Main Known Action
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cells
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT03393884I/IINewly diagnosed stage III/IV ovarian cancer (neo-adjuvant)A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerView DrugsAlabama, California, Florida, Georgia, Massachusetts, Missouri, Montana, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
CarboplatinParaplatin, NovoplatinumDNA damaging agent
GEN-1PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector GEN-1, EGEN-001, phIL-12-005/PPCIL-12 receptor agonist
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor
NCT02933073INewly diagnosed stage III/IV ovarian cancer or platinum sensitive ovarian cancer at first recurrenceA Phase I Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian CarcinomaView DrugsConnecticut
Drug(s) in Trial Other Drug Names Main Known Action
OncoImmunomeAnti-tumor immune response
NCT03054909IStage III/IV ovarian cancer with stable disease or better after first-line IV/IP cisplatin and paclitaxel therapy (maintenance)QUILT-2.021: Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only After 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal CancerView DrugsMinnesota
Drug(s) in Trial Other Drug Names Main Known Action
ALT-803Activates NK cells to stimulate immune response
NCT03607955INewly diagnosed stage III/IV ovarian cancer (neo-adjuvant)Phase IB Study of Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant ChemotherapyView DrugsMissouri, Oklahoma
Drug(s) in Trial Other Drug Names Main Known Action
AVB-S6-500GAS6 antagonist
CarboplatinParaplatin, NovoplatinumDNA damaging agent
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitor

If you have any questions or would like help with your search, please call us at: 858-264-5124 or email us at patientsupport@clearityfoundation.org.